Candidate Hepatitis C Vaccine Trials and People Who Inject Drugs: Challenges and Opportunities

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2010 Sep 14

PMID 20831914

Citations 14

Authors

Lisa Maher

Bethany White

Margaret Hellard

Annie Madden

Maria Prins

Thomas Kerr

Kimberly Page

Affiliations

Soon will be listed here.

Abstract

People who inject drugs (PWID) are at high risk of HCV. Limited evidence of the effectiveness of prevention interventions and low uptake of treatment in this group highlight the need for increased investment in biomedical interventions, notably safe and efficacious vaccines. While several candidates are currently in development, field trials in PWID present challenges, including ethical issues associated with trial literacy, informed consent and standards of care. Significant biological and social factors and differences between HIV and HCV suggest that HCV warrants targeted vaccine preparedness research to lay the groundwork for successful implementation of future trials.

Citing Articles

Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.

Feld J, Bruneau J, Dore G, Ghany M, Hansen B, Sulkowski M Clin Infect Dis. 2023; 77(Suppl 3):S262-S269.

PMID: 37579209 PMC: 10425135. DOI: 10.1093/cid/ciad362.

In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?.

Echeverria N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J World J Hepatol. 2021; 13(10):1234-1268.

PMID: 34786164 PMC: 8568586. DOI: 10.4254/wjh.v13.i10.1234.

Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada.

Fleming T, Valleriani J, Ng C, Maher L, Small W, McNeil R BMC Public Health. 2020; 20(1):1081.

PMID: 32646390 PMC: 7350753. DOI: 10.1186/s12889-020-09202-6.

Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine.

Cox A, Sulkowski M, Sugarman J Clin Infect Dis. 2020; 71(11):2986-2990.

PMID: 32442262 PMC: 7778335. DOI: 10.1093/cid/ciaa640.

Hepatitis C Vaccines, Antibodies, and T Cells.

Shoukry N Front Immunol. 2018; 9:1480.

PMID: 30002657 PMC: 6031729. DOI: 10.3389/fimmu.2018.01480.

References

Hahn J, Page-Shafer K, Lum P, Bourgois P, Stein E, Evans J . Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002; 186(11):1558-64. DOI: 10.1086/345554. View

Yazdanpanah Y, De Carli G, Migueres B, Lot F, Campins M, Colombo C . Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis. 2005; 41(10):1423-30. DOI: 10.1086/497131. View

Shepard C, Finelli L, Alter M . Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9):558-67. DOI: 10.1016/S1473-3099(05)70216-4. View

van Ameijden E, van den Hoek J, Mientjes G, Coutinho R . A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol. 1993; 9(3):255-62. DOI: 10.1007/BF00146260. View

Strickland G, El-Kamary S, Klenerman P, Nicosia A . Hepatitis C vaccine: supply and demand. Lancet Infect Dis. 2008; 8(6):379-86. DOI: 10.1016/S1473-3099(08)70126-9. View

Maher L, White B, Donald A, Bates A, Enriquez J, Pham S . Using ethnographic fieldwork to inform hepatitis C vaccine preparedness studies with people who inject drugs. Int J Drug Policy. 2009; 21(3):194-201. DOI: 10.1016/j.drugpo.2009.04.004. View

Campbell J, Garfein R, Thiede H, Hagan H, Ouellet L, Golub E . Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug Alcohol Depend. 2007; 91 Suppl 1:S64-72. DOI: 10.1016/j.drugalcdep.2006.09.022. View

Harrison 3rd R . Impact of biomedical research on African Americans. J Natl Med Assoc. 2003; 93(3 Suppl):6S-7S. PMC: 2593959. View

Davis M, Rhodes T, Martin A . Preventing hepatitis C: 'common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs. Soc Sci Med. 2004; 59(9):1807-18. DOI: 10.1016/j.socscimed.2004.02.021. View

10.

Dore G, Micallef J . Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity?. Hepatology. 2007; 45(5):1330. DOI: 10.1002/hep.21577. View

11.

Newman P, Duan N, Lee S, Rudy E, Seiden D, Kakinami L . HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine. 2005; 24(12):2094-101. PMC: 2819665. DOI: 10.1016/j.vaccine.2005.11.013. View

12.

Kamal S, Fouly A, Kamel R, Hockenjos B, Al Tawil A, Khalifa K . Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006; 130(3):632-8. DOI: 10.1053/j.gastro.2006.01.034. View

13.

Lagakos S, Gable A . Challenges to HIV prevention--seeking effective measures in the absence of a vaccine. N Engl J Med. 2008; 358(15):1543-5. DOI: 10.1056/NEJMp0802028. View

14.

Lauer G, Chung R . Vaccine-induced T-cell responses against HCV: one step taken, more to follow. Gastroenterology. 2007; 132(4):1626-8. DOI: 10.1053/j.gastro.2007.03.010. View

15.

Grebely J, Conway B, Raffa J, Lai C, Krajden M, Tyndall M . Hepatitis C virus reinfection in injection drug users. Hepatology. 2006; 44(5):1139-45. DOI: 10.1002/hep.21376. View

16.

Gowans E, Roberts S, Jones K, Dinatale I, Latour P, Chua B . A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol. 2010; 53(4):599-607. PMC: 2930140. DOI: 10.1016/j.jhep.2010.05.007. View

17.

Lugoboni F, Migliozzi S, Schiesari F, Pauletto N, Bovo G, Ciaffoni S . Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine. 1997; 15(9):1014-6. DOI: 10.1016/s0264-410x(96)00290-3. View

18.

van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F . Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis. 2004; 189(2):292-302. DOI: 10.1086/380821. View

19.

Newman P, Logie C . HIV vaccine acceptability: a systematic review and meta-analysis. AIDS. 2010; 24(11):1749-56. DOI: 10.1097/qad.0b013e32833adbe8. View

20.

Seal K, Kral A, Lorvick J, McNees A, Gee L, Edlin B . A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend. 2003; 71(2):127-31. DOI: 10.1016/s0376-8716(03)00074-7. View